Two weeks of heart monitoring did not reduce fainting spells

Giving people who faint from an unexplained cause a 14-day wearable heart monitor did not leave them with fewer fainting episodes a year later than standard care, a large randomised trial has found [s1]. In 2,234 patients across 45 UK hospitals, the average number of patient-reported syncope episodes at one year was 1.37 in the monitored group and 1.58 with usual care — a difference that was not statistically significant [s1].

Syncope — a transient loss of consciousness from a temporary drop in blood flow to the brain — is one of the harder problems in emergency medicine. Most cases are benign, but a minority are caused by a dangerous heart-rhythm disturbance, and telling those apart is difficult when the episode is over by the time the patient reaches hospital [s1]. The intuitive fix is to record the heart continuously for days in the hope of catching an arrhythmia on the rare occasion it recurs. The ASPIRED trial tested whether doing that early actually helps patients — and the answer, on its chosen measure, was no [s1][s2].

What the trial did

ASPIRED was an open-label, randomised, controlled trial that enrolled adults whose syncope remained unexplained after evaluation in the emergency department [s1]. Participants were assigned in equal numbers to receive 14-day ambulatory ECG monitoring (1,123 patients) or the standard care offered for unexplained syncope at each site (1,111 patients) [s1]. Their mean age was 58.3 years and 52.1% were male [s1]. The primary outcome was deliberately patient-centred: not how many arrhythmias were detected, but the mean number of syncope episodes each patient reported over the following year [s1].

After excluding those who completed no follow-up, 1,970 patients entered the primary analysis [s1]. The mean number of reported episodes at one year was 1.37 (standard deviation 5.10) in the monitoring group and 1.58 (8.56) in the standard-care group, an incidence rate ratio of 0.89 (95% confidence interval, 0.68 to 1.18; P = 0.42) [s1]. A confidence interval that comfortably straddles 1.0, together with a P value of 0.42, means the trial found no reliable evidence that monitoring reduced recurrent fainting [s1].

There was also a cost. The monitoring group reported 49 adverse events against 8 in the standard-care group, with one serious adverse event in each group [s1] — most of the excess being the minor skin and wear-related problems that come with strapping a device to the chest for two weeks, but a reminder that even a low-risk test is not free of harm.

Why a negative result here is useful

The instinct to equate more monitoring with better care is strong, and this trial is a clean illustration of why that instinct needs testing. A longer or continuous monitor will almost certainly detect more rhythm abnormalities than standard care — that is close to arithmetic. But detecting an arrhythmia is only worthwhile if acting on it changes what happens to the patient, and ASPIRED measured the thing patients actually care about: whether they keep fainting [s1]. On that measure, immediate 14-day monitoring did not move the needle.

The same distinction runs through much of cardiac diagnostics. It is the gap between the diagnostic yield of AI-read ECG screening and proof that screening improves outcomes, and it echoes the debate over consumer smartwatches that flag atrial fibrillation — where finding more arrhythmias raises, rather than settles, the question of what to do about them. Detection and benefit are separate claims, and a test earns its place only by delivering the second.

The limits, and what to watch

The trial's design carries caveats. It was open-label, so patients and clinicians knew who was being monitored, which can influence how episodes are reported [s1]. The primary outcome relied on patient self-report of fainting rather than an objective adjudication, and a monitor that changes management for a small high-risk subgroup could still be valuable even when the average across everyone shows no effect [s1]. What ASPIRED argues against is the blanket assumption that early ambulatory monitoring helps every patient with unexplained syncope — not the targeted use of monitoring in those with genuine red flags for a cardiac cause.

The result is a well-powered null: two weeks of ECG monitoring, given to a broad population soon after an unexplained faint, did not reduce recurrent syncope over the following year [s1]. This article describes trial findings and is not medical advice.

Sources

• Immediate Ambulatory Electrocardiographic Monitoring in Syncope — New England Journal of Medicine, published online August 2026
• ASPIRED trial registration (ISRCTN10278811) — ISRCTN Registry